Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis -

Cardiovascular Outcomes of Calcium-Free vs Calcium-Based Phosphate Binders in Patients 65 Years or Older With End-stage Renal Disease Requiring Hemodialysis
Information type: Other primary research
Source: JAMA Internal Medicine
Specialities: Cardiovascular system disorders | Renal and urologic disorders
Summary
Observational analysis of 4704 patients from the US Renal Data System shows a similar risk of cardiovascular events and death for those treated with sevelamer vs calcium acetate after adjusting for potential confounders, including serum calcium and phosphorous levels.
UKMi comment
The study evaluated patients undergoing haemodialysis who were 65 years or older and had initiated phosphate binder treatment within 6 months of starting dialysis. The study found no significant difference in the risk of fatal or nonfatal cardiovascular events (473 events; hazard ratio, 1.00) or all-cause mortality (238 events; HR 0.96) comparing calcium acetate with sevelamer treatment.
Related links: Editorial